BPH Surgical Treatment Market - Global Forecast To 2030
商品番号 : SMB-73462
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年2月 |
| ページ数 | 329 |
| 図表数 | 427 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The global BPH surgical treatment market is valued at an estimated 12.62 billion in 2024 and is projected to reach USD 17.19 billion by 2030, at a CAGR of 5.3% during the forecast period.
世界の前立腺肥大症の外科治療市場は、2024 年に推定 126 億 2,000 万ドルと評価され、予測期間中の CAGR は 5.3% で、2030 年までに 171 億 9 千万米ドルに達すると予測されています。
The growing elderly male population is leading to the cause of BPH patients globally. Therefore, BPH is related to age, and aging is known as a risk factor for BPH. Approximately 50% of men over the age of 50 and around 80% of men over the age of 70 are under the influence of BPH.
高齢男性人口の増加は、世界的に前立腺肥大症患者の原因となっています。したがって、前立腺肥大症は年齢と関連しており、加齢は前立腺肥大症の危険因子として知られています。 50歳以上の男性の約50％、70歳以上の男性の約80％が前立腺肥大症の影響下にあります。
In 2023, the alpha-blockers segment accounted for the largest share of the BPH surgical treatment market, by drug type.
Alpha-blockers, 5-alpha reductase inhibitors, and other drug types make up the drug-type-based segments of the BPH surgical treatment market. Market share for BPH surgical treatment was highest in the Alpha-blockers in 2023. This is mainly due to the Alpha-blockers being recommended as first-line treatment for BPH. α-blockers relax the smooth muscle of the prostate and bladder neck to improve urine flow and reduce bladder outlet obstruction.
“The home care settings segment is projected to witness the highest growth rate in BPH surgical treatment market, by the end-user, during the forecast period.”
Based on end users, the BPH surgical treatment market is segmented into hospitals, ambulatory surgery centers & clinics, and home care settings. The driving factors that force home care settings to BPH surgical treatment is that the patients prefer taking medicine over surgery in most cases, which has supported the growth of this segment. Also, patients avoid surgical or minimally invasive procedures (e.g., TURP, laser therapy) due to potential complications, discomfort, or recovery time.
“The Asia Pacific region is projected to witness highest growth rate in the BPH surgical treatment market during the forecast period”
The global BPH surgical treatment market is segmented into six regions – North America, Europe, Asia Pacific, the Middle East & Africa, Latin America, and the GCC Countries. Throughout the forecast period, the BPH surgical treatment market is expected to grow at the fastest rate in the Asia Pacific region. The demand for BPH surgical treatment in the APAC is mainly driven by the growing geriatric population, the increasing GDP of Asian countries, the rising healthcare expenditure in the APAC countries, and growing public awareness.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 – 50%, Tier 2 – 30%, and Tier 3 – 20%
- By Designation: C-level – 25%, D-level – 20%, and Others – 55%
- By Region: North America – 35%, Europe – 32%, Asia Pacific – 21%, Latin America – 8%, Middle East & Africa – 1%, and the GCC Countries – 3%
Lists of Companies Profiled in the Report:
GlaxoSmithKline PLC (UK), Eli Lilly and Company (US), Astellas Pharma Inc.(Japan), Viatris Inc. (US), Asahi Kasei Corporation (Japan), Organon & Co. (US), Alembic Pharmaceuticals Limited (India), Teleflex Incorporated (US) and Boston Scientific Corporation (US), Olympus Corporation (Japan), Procept BioRobotics Corporation (US), Coloplast Group (Denmark), IPG Photonics Corporation (Russia), ProstaLund AB (Sweden), Karl Storz Se & Co. KG (Germany), Richard Wolf Gmbh (Germany), and Quanta System (Italy), Asclepion Laser Technologies GmbH (Germany), Cook Medical (US), SRS Medical (US), Pnn Medical A/S (Denmark), Allium Ltd. (Israel), Urologix, LLC (US), and Medifocus, Inc. (Canada).
Research Coverage:
In this report, the BPH surgical treatment market has been categorized based on drug type (alpha-blockers, 5-alpha reductase inhibitors, and other drug types), type (Transurethral Resection of the Prostate (TURP), Laser Surgery, UroLift Procedure, Rezūm Procedure, Robot-assisted waterjet ablation, Prostatic Stenting, Transurethral Microwave Thermotherapy (TUMT), Transurethral Needle Ablation of the Prostate (TUNA), Prostatic arterial embolization (PAE) and others) end user (hospitals, ASCs & clinics, and home care settings), therapy (monotherapy and combination drug therapy), and region (Europe, Middle East & Africa, North America, Latin America, Asia Pacific, and the GCC Countries).
Comprehensive information regarding the main drivers, barriers, opportunities, and challenges influencing the BPH surgical treatment market’s expansion is included in detail in this study. An exhaustive study of the key players in the cochlear implants market has been done to provide insights into their business profiles, products offered, noteworthy strategies, product launches, and approvals, and other recent activities pertaining to the market.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall BPH surgical treatment market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, challenges, opportunities, and restraints.
The report provides insights on the following pointers:
- Analysis of key drivers: (Expanding aging population and increasing prevalence of BPH, Rising cases of obesity in males, and Growing preference for minimally invasive surgeries), restraints (High cost of cochlear implants and associated surgeries and surgical risks, procedural complications, and long post-surgery rehabilitation), opportunities (Side effects associated with BPH medications and High cost of BPH surgical treatment), and challenges (Shortage of skilled professionals, Low awareness regarding prostate health and Product recalls) influencing the growth of the in BPH surgical treatment market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the BPH surgical treatment market across varied regions.
- Product Development/Innovation: Comprehensive information about product development and new technologies – the report analyses the BPH surgical treatment market.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the BPH surgical treatment market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like GlaxoSmithKline PLC (UK), Eli Lilly and Company (US), Astellas Pharma Inc. (Japan), Viatris Inc. (US), Asahi Kasei Corporation (Japan), Organon & Co. (US), Alembic Pharmaceuticals Limited (India), Teleflex Incorporated (US) and Boston Scientific Corporation (US), Olympus Corporation (Japan), Procept BioRobotics Corporation (US), Coloplast Group (Denmark) and IPG Photonics Corporation (Russia) in the BPH surgical treatment market strategies.
Table of Contents
1 INTRODUCTION 29
1.1 STUDY OBJECTIVES 29
1.2 MARKET DEFINITION 29
1.3 STUDY SCOPE 30
1.3.1 MARKET SCOPE 30
1.3.2 INCLUSIONS & EXCLUSIONS 31
1.3.3 YEARS CONSIDERED 31
1.3.4 CURRENCY CONSIDERED 32
1.4 STAKEHOLDERS 32
1.5 LIMITATIONS 32
1.6 SUMMARY OF CHANGES 32
2 RESEARCH METHODOLOGY 34
2.1 RESEARCH DATA 34
2.1.1 SECONDARY DATA 34
2.1.1.1 Key data from secondary sources 35
2.1.2 PRIMARY DATA 36
2.1.2.1 Primary sources 36
2.1.2.2 Key data from primary sources 37
2.1.2.3 Key industry insights 38
2.1.2.4 Breakdown of primary interviews 38
2.2 MARKET SIZE ESTIMATION 39
2.2.1 BOTTOM-UP APPROACH 39
2.2.1.1 Approach 1: Company revenue estimation approach, by type 40
2.2.1.2 Approach 1: Company revenue estimation approach, by drug type 41
2.2.2 TOP-DOWN APPROACH 44
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 45
2.4 MARKET SHARE ANALYSIS 46
2.4.1 STUDY ASSUMPTIONS 46
2.4.2 GROWTH RATE ASSUMPTIONS 46
2.5 RESEARCH LIMITATIONS 47
2.5.1 METHODOLOGY-RELATED LIMITATIONS 47
2.5.2 SCOPE-RELATED LIMITATIONS 47
2.6 RISK ASSESSMENT 47
3 EXECUTIVE SUMMARY 48
4 PREMIUM INSIGHTS 53
4.1 BPH SURGICAL TREATMENT MARKET OVERVIEW 53
4.2 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE AND COUNTRY (2024) 54
4.3 BPH SURGICAL TREATMENT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 55
4.4 BPH SURGICAL TREATMENT MARKET: REGIONAL MIX (2024–2030) 56
5 MARKET OVERVIEW 57
5.1 INTRODUCTION 57
5.2 MARKET DYNAMICS 57
5.2.1 DRIVERS 58
5.2.1.1 Expanding aging population and increasing prevalence of benign prostatic hyperplasia 58
5.2.1.2 Rising cases of obesity in males 58
5.2.1.3 Growing preference for minimally invasive surgeries 59
5.2.2 RESTRAINTS 60
5.2.2.1 Side effects associated with BPH medications 60
5.2.2.2 High cost of BPH surgical treatment 61
5.2.3 OPPORTUNITIES 61
5.2.3.1 High growth potential of emerging economies 61
5.2.3.2 Favorable funding investments for BHP drug development 62
5.2.4 CHALLENGES 63
5.2.4.1 Shortage of skilled professionals 63
5.2.4.2 Low awareness regarding prostate health 63
5.2.4.3 Product recalls 64
5.3 VALUE CHAIN ANALYSIS 64
5.4 SUPPLY CHAIN ANALYSIS 66
5.5 ECOSYSTEM ANALYSIS 67
5.6 PORTER’S FIVE FORCES ANALYSIS 69
5.6.1 THREAT OF NEW ENTRANTS 70
5.6.2 THREAT OF SUBSTITUTES 70
5.6.3 BARGAINING POWER OF BUYERS 70
5.6.4 BARGAINING POWER OF SUPPLIERS 70
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 70
5.7 KEY STAKEHOLDERS & BUYING CRITERIA 71
5.7.1 KEY STAKEHOLDERS IN BUYING PROCESS 71
5.7.2 BUYING CRITERIA 71
5.8 REGULATORY SCENARIO 72
5.8.1 PHARMACEUTICAL INDUSTRY 72
5.8.1.1 Regulatory requirements 73
5.8.1.1.1 EU regulations 73
5.8.1.1.2 US regulations 73
5.8.2 MEDICAL DEVICES INDUSTRY 73
5.8.2.1 US 73
5.8.2.2 Canada 74
5.8.2.3 Europe 75
5.8.2.4 Asia Pacific 76
5.8.2.4.1 Japan 76
5.8.2.4.2 China 77
5.8.2.4.3 India 78
5.8.2.5 Latin America 79
5.8.2.5.1 Brazil 79
5.8.2.5.2 Mexico 79
5.8.2.6 Middle East 79
5.8.2.7 Africa 80
5.8.3 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
5.9 PRICING ANALYSIS 82
5.9.1 AVERAGE SELLING PRICE TREND FOR UROLIFT, BY REGION, 2021−2023 82
5.9.2 AVERAGE SELLING PRICING TREND FOR AVODART, BY REGION, 2021−2023 82
5.9.3 AVERAGE SELLING PRICING TREND FOR BPH SURGICAL TREATMENT PROCEDURES, 2021−2023 83
5.10 TECHNOLOGY ANALYSIS 83
5.10.1 KEY TECHNOLOGIES 83
5.10.1.1 Minimally invasive surgical techniques 83
5.10.2 COMPLEMENTARY TECHNOLOGIES 84
5.10.2.1 Robotic & AI-assisted surgical systems 84
5.10.3 ADJACENT TECHNOLOGIES 84
5.10.3.1 MRI-ultrasound imaging 84
5.11 PESTLE ANALYSIS 85
5.12 PATENT ANALYSIS 86
5.13 TRADE ANALYSIS 90
5.13.1 TRADE ANALYSIS FOR ENDOSCOPES 90
5.13.2 TRADE ANALYSIS FOR TADALAFIL 91
5.14 KEY CONFERENCES & EVENTS, 2025−2026 92
5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 93
5.16 IMPACT OF GENERATIVE AI/AI ON BPH SURGICAL TREATMENT MARKET 94
5.17 INVESTMENT & FUNDING SCENARIO 94
6 BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE 95
6.1 INTRODUCTION 96
6.1.1 ALPHA-BLOCKERS 98
6.1.1.1 Tamsulosin 100
6.1.1.1.1 Oldest prescribed drug with minimal effects on blood pressure to fuel uptake 100
6.1.1.2 Silodosin 103
6.1.1.2.1 Launch of generics to boost demand 103
6.1.1.3 Alfuzosin 105
6.1.1.3.1 Associated side effects to restrain market adoption 105
6.1.1.4 Doxazosin 108
6.1.1.4.1 Ability to provide long-term results to fuel uptake 108
6.1.1.5 Other alpha-blockers 111
6.1.2 5-ALPHA REDUCTASE INHIBITORS 113
6.1.2.1 Dutasteride 116
6.1.2.1.1 Slow but gradual reduction in symptoms to boost demand 116
6.1.2.2 Finasteride 118
6.1.2.2.1 Ability to decrease PSA levels to support market growth 118
6.1.3 OTHER DRUG TYPES 121
7 BPH SURGICAL TREATMENT MARKET, BY TYPE 124
7.1 INTRODUCTION 125
7.1.1 TRANSURETHRAL RESECTION OF THE PROSTATE (TURP) 128
7.1.1.1 Gold standard for BPH treatment to boost demand 128
7.1.2 LASER SURGERIES 131
7.1.2.1 Evolution in lasers and high efficacy to boost demand 131
7.1.3 UROLIFT PROCEDURES 133
7.1.3.1 High safety and convenience to boost demand 133
7.1.4 REZŪM PROCEDURES 136
7.1.4.1 Convenience of being conducted in outpatient settings to support market growth 136
7.1.5 ROBOT-ASSISTED WATERJET ABLATION 138
7.1.5.1 Advanced real-time capabilities with image-guided features to propel market 138
7.1.6 PROSTATIC STENTS 141
7.1.6.1 Temporarily designed for short-term use to support market growth 141
7.1.7 TRANSURETHRAL MICROWAVE THERMOTHERAPY (TUMT) 144
7.1.7.1 Lower risk of bleeding without hospitalization to fuel market 144
7.1.8 TRANSURETHRAL NEEDLE ABLATION OF THE PROSTATE (TUNA) 146
7.1.8.1 Favorable reimbursement policies to boost demand 146
7.1.9 PROSTATIC ARTERIAL EMBOLIZATION (PAE) 149
7.1.9.1 Minimally invasive technique to fuel uptake 149
7.1.10 OTHER PROCEDURES 152
8 BPH SURGICAL TREATMENT MARKET, BY THERAPY 155
8.1 INTRODUCTION 156
8.2 MONOTHERAPY 158
8.2.1 UTILIZATION OF SINGLE MEDICATION TO PROPEL MARKET 158
8.3 COMBINATION DRUG THERAPY 160
8.3.1 HIGH UTILIZATION FOR PATIENTS WITH RAPID PROGRESSION RATES TO DRIVE MARKET 160
9 BPH SURGICAL TREATMENT MARKET, BY END USER 164
9.1 INTRODUCTION 165
9.2 HOSPITALS 165
9.2.1 HIGH PURCHASING POWER FOR ADVANCED BPH SURGICAL EQUIPMENT TO DRIVE MARKET 165
9.3 AMBULATORY SURGERY CENTERS & CLINICS 168
9.3.1 LOWER COST AND SHORTER PATIENT STAYS TO PROPEL MARKET 168
9.4 HOME CARE SETTINGS 171
9.4.1 CONVENIENCE AND COST-EFFICIENT BENEFITS TO FUEL MARKET 171
10 BPH SURGICAL TREATMENT MARKET, BY REGION 175
10.1 INTRODUCTION 176
10.2 NORTH AMERICA 177
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 177
10.2.2 US 181
10.2.2.1 Presence of key medical device manufacturers to boost demand 181
10.2.3 CANADA 184
10.2.3.1 Favorable federal funding for advanced BPH products to fuel market 184
10.3 EUROPE 187
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 188
10.3.2 GERMANY 191
10.3.2.1 Increasing healthcare expenditure to drive market 191
10.3.3 UK 194
10.3.3.1 Availability of innovative treatment options for UTIs to drive market 194
10.3.4 FRANCE 197
10.3.4.1 Favorable private & public healthcare investments to fuel market 197
10.3.5 ITALY 200
10.3.5.1 Rising geriatric population and subsequent rise in obesity to propel market 200
10.3.6 SPAIN 203
10.3.6.1 Increasing uptake of UroLift procedures to drive market 203
10.3.7 REST OF EUROPE 206
10.4 ASIA PACIFIC 209
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 209
10.4.2 JAPAN 214
10.4.2.1 Mandatory health insurance programs to fuel uptake 214
10.4.3 CHINA 217
10.4.3.1 Rising demand for diagnostic procedures to drive market 217
10.4.4 INDIA 220
10.4.4.1 Expanding target patient population to drive market 220
10.4.5 AUSTRALIA 223
10.4.5.1 High prevalence of obesity to support market growth 223
10.4.6 REST OF ASIA PACIFIC 226
10.5 LATIN AMERICA 229
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 229
10.5.2 BRAZIL 232
10.5.2.1 Rising incidence of cancer to support market growth 232
10.5.3 MEXICO 235
10.5.3.1 Popularity in medical tourism to drive market 235
10.5.4 REST OF LATIN AMERICA 238
10.6 MIDDLE EAST & AFRICA 241
10.6.1 DEMAND FOR ADVANCED HEALTHCARE DIAGNOSTICS TO FUEL UPTAKE 241
10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 242
10.7 GCC COUNTRIES 245
10.7.1 RISING HEALTHCARE BUDGETS AND GROWING AWARENESS OF BPH TO SUPPORT MARKET GROWTH 245
10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES 246
11 COMPETITIVE LANDSCAPE 250
11.1 OVERVIEW 250
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 250
11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN BPH SURGICAL TREATMENT MARKET 250
11.3 REVENUE ANALYSIS, 2021−2023 252
11.4 MARKET SHARE ANALYSIS, 2023 253
11.5 COMPANY EVALUATION MATRIX, BY DRUG TYPE: KEY PLAYERS, 2023 256
11.5.1 STARS 256
11.5.2 EMERGING LEADERS 256
11.5.3 PERVASIVE PLAYERS 256
11.5.4 PARTICIPANTS 256
11.6 COMPANY EVALUATION MATRIX, BY TYPE: KEY PLAYERS, 2023 258
11.6.1 STARS 258
11.6.2 EMERGING LEADERS 258
11.6.3 PERVASIVE PLAYERS 258
11.6.4 PARTICIPANTS 258
11.6.5 COMPANY FOOTPRINT: KEY PLAYERS (DRUG TYPE AND TYPE), 2023 260
11.6.5.1 Company footprint 260
11.6.5.2 Region footprint 261
11.6.5.3 Drug type footprint 261
11.6.5.4 Type footprint 262
11.6.5.5 End-user footprint 262
11.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 263
11.7.1 PROGRESSIVE COMPANIES 263
11.7.2 RESPONSIVE COMPANIES 263
11.7.3 DYNAMIC COMPANIES 263
11.7.4 STARTING BLOCKS 263
11.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 265
11.7.5.1 Detailed list of key startups/SMEs 265
11.7.5.2 Competitive benchmarking of key startups 265
11.8 COMPANY VALUATION & FINANCIAL METRICS 266
11.9 BRAND/PRODUCT COMPARISON 267
11.10 COMPETITIVE SCENARIO 267
11.10.1 PRODUCT LAUNCHES & APPROVALS 267
11.10.2 DEALS 268
11.10.3 EXPANSIONS 269
12 COMPANY PROFILES 270
12.1 KEY PLAYERS 270
12.1.1 GLAXOSMITHKLINE PLC 270
12.1.1.1 Business overview 270
12.1.1.2 Products offered 272
12.1.1.3 Recent developments 272
12.1.1.3.1 Deals 272
12.1.1.4 MnM view 273
12.1.1.4.1 Key strengths 273
12.1.1.4.2 Strategic choices 273
12.1.1.4.3 Weaknesses & competitive threats 273
12.1.2 ELI LILLY AND COMPANY 274
12.1.2.1 Business overview 274
12.1.2.2 Products offered 275
12.1.2.3 Recent developments 276
12.1.2.3.1 Deals 276
12.1.2.4 MnM view 276
12.1.2.4.1 Key strengths 276
12.1.2.4.2 Strategic choices 276
12.1.2.4.3 Weaknesses & competitive threats 276
12.1.3 TELEFLEX INCORPORATED 277
12.1.3.1 Business overview 277
12.1.3.2 Products offered 278
12.1.3.3 Recent developments 279
12.1.3.3.1 Product launches & approvals 279
12.1.3.4 MnM view 279
12.1.3.4.1 Key strengths 279
12.1.3.4.2 Strategic choices 279
12.1.3.4.3 Weaknesses & competitive threats 280
12.1.4 BOSTON SCIENTIFIC CORPORATION 281
12.1.4.1 Business overview 281
12.1.4.2 Recent developments 283
12.1.4.2.1 Deals 283
12.1.4.2.2 Expansions 283
12.1.4.3 MnM view 284
12.1.4.3.1 Key strengths 284
12.1.4.3.2 Strategic choices 284
12.1.4.3.3 Weaknesses & competitive threats 284
12.1.5 PROCEPT BIOROBOTICS CORPORATION 285
12.1.5.1 Business overview 285
12.1.5.2 Products offered 286
12.1.5.3 Recent developments 287
12.1.5.3.1 Product approvals 287
12.1.5.3.2 Expansions 287
12.1.5.4 MnM view 287
12.1.5.4.1 Key strengths 287
12.1.5.4.2 Strategic choices 287
12.1.5.4.3 Weaknesses & competitive threats 288
12.1.6 ASTELLAS PHARMA INC. 289
12.1.6.1 Business overview 289
12.1.6.2 Products offered 290
12.1.7 ALEMBIC PHARMACEUTICALS LIMITED 291
12.1.7.1 Business overview 291
12.1.7.2 Products offered 292
12.1.8 ASAHI KASEI CORPORATION 293
12.1.8.1 Business overview 293
12.1.8.2 Products offered 295
12.1.9 ORGANON & CO. 296
12.1.9.1 Business overview 296
12.1.9.2 Products offered 297
12.1.9.3 Recent developments 297
12.1.9.3.1 Deals 297
12.1.10 OLYMPUS CORPORATION 298
12.1.10.1 Business overview 298
12.1.10.2 Products offered 300
12.1.10.3 Recent developments 300
12.1.10.3.1 Deals 300
12.1.11 COLOPLAST GROUP 301
12.1.11.1 Business overview 301
12.1.11.2 Products offered 303
12.1.12 IPG PHOTONICS CORPORATION 304
12.1.12.1 Business overview 304
12.1.12.2 Products offered 305
12.1.13 VIATRIS INC. 306
12.1.13.1 Business overview 306
12.1.13.2 Products offered 307
12.1.14 ABBVIE INC. 308
12.1.14.1 Business overview 308
12.1.14.2 Products offered 309
12.1.14.3 Recent developments 310
12.1.14.3.1 Deals 310
12.1.15 PROSTALUND AB 311
12.1.15.1 Business overview 311
12.1.15.2 Products offered 312
12.2 OTHER PLAYERS 313
12.2.1 KARL STORZ SE & CO. KG 313
12.2.2 RICHARD WOLF GMBH 313
12.2.3 UNILAB, INC. 314
12.2.4 BIOLITEC HOLDING GMBH & CO KG 314
12.2.5 UROLOGIX, LLC. 315
12.2.6 ADVIN HEALTH CARE 315
12.2.7 MEDIFOCUS, INC. 316
12.2.8 JENASURGICAL (ASCLEPION LASER TECHNOLOGIES GMBH) 316
12.2.9 PNN MEDICAL A/S 317
12.2.10 SURGICAL LASERS INC. 317
12.2.11 QUANTA SYSTEM 318
12.2.12 ALLIUM LTD. 318
12.2.13 SRS MEDICAL 319
12.2.14 LABORIE MEDICAL TECHNOLOGIES 319
12.2.15 COOK MEDICAL 320
13 APPENDIX 321
13.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 325
13.2 CUSTOMIZATION OPTIONS 327
13.3 RELATED REPORTS 327
13.4 AUTHOR DETAILS 328
LIST OF TABLES
TABLE 1 BPH SURGICAL TREATMENT MARKET: RISK ASSESSMENT ANALYSIS 47
TABLE 2 ASSOCIATED SIDE EFFECTS OF BPH DRUGS 60
TABLE 3 PRODUCT RECALLS IN BPH TREATMENT MARKET 64
TABLE 4 BPH SURGICAL TREATMENT MARKET: ROLE OF COMPANIES IN ECOSYSTEM 68
TABLE 5 BPH SURGICAL TREATMENT MARKET: PORTER’S FIVE FORCES FACTOR ANALYSIS 69
TABLE 6 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 71
TABLE 7 KEY BUYING CRITERIA (RANKING) FOR BPH SURGICAL TREATMENT MARKET,
BY END USER 72
TABLE 8 US FDA: MEDICAL DEVICE CLASSIFICATION 74
TABLE 9 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 74
TABLE 10 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 75
TABLE 11 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 76
TABLE 12 CHINA: CLASSIFICATION OF MEDICAL DEVICES 77
TABLE 13 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT
AGENCIES, AND OTHER ORGANIZATIONS 80
TABLE 14 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 80
TABLE 15 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 81
TABLE 16 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 81
TABLE 17 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 18 AVERAGE SELLING PRICE TREND FOR UROLIFT, BY REGION, 2021–2023 82
TABLE 19 AVERAGE SELLING PRICE TREND OF DUTASTERIDE (AVODART), BY REGION,
2021–2023 82
TABLE 20 AVERAGE SELLING PRICING TREND FOR BPH SURGICAL TREATMENT PROCEDURES, 2021–2023 83
TABLE 21 IMPORT DATA FOR ENDOSCOPES (VALUE) BY COUNTRY,
2019–2023 (USD THOUSAND) 90
TABLE 22 EXPORT DATA FOR ENDOSCOPES (VALUE) BY COUNTRY,
2019–2023 (USD THOUSAND) 90
TABLE 23 IMPORT DATA FOR TADALAFIL (VALUE) BY COUNTRY,
2019−2023 (USD THOUSAND) 91
TABLE 24 EXPORT DATA FOR TADALAFIL (VALUE) BY COUNTRY,
2019−2023 (USD THOUSAND) 91
TABLE 25 BPH SURGICAL TREATMENT MARKET: KEY CONFERENCES & EVENTS, 2025–2026 92
TABLE 26 BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022–2030 (USD MILLION) 96
TABLE 27 BPH DRUG TYPE MARKET, BY REGION, 2022–2030 (USD MILLION) 96
TABLE 28 NORTH AMERICA: BPH DRUG TYPE MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 97
TABLE 29 EUROPE: BPH DRUG TYPE MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 97
TABLE 30 ASIA PACIFIC: BPH DRUG TYPE MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 97
TABLE 31 LATIN AMERICA: BPH DRUG TYPE MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 98
TABLE 32 ALPHA-BLOCKERS MARKET, BY TYPE, 2022–2030 (USD MILLION) 98
TABLE 33 ALPHA-BLOCKERS MARKET, BY REGION, 2022–2030 (USD MILLION) 99
TABLE 34 NORTH AMERICA: ALPHA-BLOCKERS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 99
TABLE 35 EUROPE: ALPHA-BLOCKERS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 99
TABLE 36 ASIA PACIFIC: ALPHA-BLOCKERS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 100
TABLE 37 LATIN AMERICA: ALPHA-BLOCKERS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 100
TABLE 38 ALPHA-BLOCKERS MARKET FOR TAMSULOSIN, BY REGION,
2022–2030 (USD MILLION) 101
TABLE 39 NORTH AMERICA: ALPHA-BLOCKERS MARKET FOR TAMSULOSIN, BY COUNTRY, 2022–2030 (USD MILLION) 101
TABLE 40 EUROPE: ALPHA-BLOCKERS MARKET FOR TAMSULOSIN, BY COUNTRY,
2022–2030 (USD MILLION) 102
TABLE 41 ASIA PACIFIC: ALPHA-BLOCKERS MARKET FOR TAMSULOSIN, BY COUNTRY,
2022–2030 (USD MILLION) 102
TABLE 42 LATIN AMERICA: ALPHA-BLOCKERS MARKET FOR TAMSULOSIN,
BY COUNTRY, 2022–2030 (USD MILLION) 103
TABLE 43 ALPHA-BLOCKERS MARKET FOR SILODOSIN, BY REGION,
2022–2030 (USD MILLION) 103
TABLE 44 NORTH AMERICA: ALPHA-BLOCKERS MARKET FOR SILODOSIN,
BY COUNTRY, 2022–2030 (USD MILLION) 104
TABLE 45 EUROPE: ALPHA-BLOCKERS MARKET FOR SILODOSIN, BY COUNTRY,
2022–2030 (USD MILLION) 104
TABLE 46 ASIA PACIFIC: ALPHA-BLOCKERS MARKET FOR SILODOSIN, BY COUNTRY,
2022–2030 (USD MILLION) 105
TABLE 47 LATIN AMERICA: ALPHA-BLOCKERS MARKET FOR SILODOSIN, BY COUNTRY,
2022–2030 (USD MILLION) 105
TABLE 48 ALPHA-BLOCKERS MARKET FOR ALFUZOSIN, BY REGION,
2022–2030 (USD MILLION) 106
TABLE 49 NORTH AMERICA: ALPHA-BLOCKERS MARKET FOR ALFUZOSIN, BY COUNTRY, 2022–2030 (USD MILLION) 106
TABLE 50 EUROPE: ALPHA-BLOCKERS MARKET FOR ALFUZOSIN, BY COUNTRY,
2022–2030 (USD MILLION) 107
TABLE 51 ASIA PACIFIC: ALPHA-BLOCKERS MARKET FOR ALFUZOSIN, BY COUNTRY,
2022–2030 (USD MILLION) 107
TABLE 52 LATIN AMERICA: ALPHA-BLOCKERS MARKET FOR ALFUZOSIN, BY COUNTRY,
2022–2030 (USD MILLION) 108
TABLE 53 ALPHA-BLOCKERS MARKET FOR DOXAZOSIN, BY REGION,
2022–2030 (USD MILLION) 109
TABLE 54 NORTH AMERICA: ALPHA-BLOCKERS MARKET FOR DOXAZOSIN, BY COUNTRY, 2022–2030 (USD MILLION) 109
TABLE 55 EUROPE: ALPHA-BLOCKERS MARKET FOR DOXAZOSIN, BY COUNTRY,
2022–2030 (USD MILLION) 110
TABLE 56 ASIA PACIFIC: ALPHA-BLOCKERS MARKET FOR DOXAZOSIN, BY COUNTRY,
2022–2030 (USD MILLION) 110
TABLE 57 LATIN AMERICA: ALPHA-BLOCKERS MARKET FOR DOXAZOSIN, BY COUNTRY, 2022–2030 (USD MILLION) 111
TABLE 58 OTHER ALPHA-BLOCKERS MARKET, BY REGION, 2022–2030 (USD MILLION) 111
TABLE 59 NORTH AMERICA: OTHER ALPHA-BLOCKERS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 112
TABLE 60 EUROPE: OTHER ALPHA-BLOCKERS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 112
TABLE 61 ASIA PACIFIC: OTHER ALPHA-BLOCKERS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 113
TABLE 62 LATIN AMERICA: OTHER ALPHA-BLOCKERS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 113
TABLE 63 5-ALPHA REDUCTASE INHIBITORS MARKET, BY TYPE, 2022–2030 (USD MILLION) 114
TABLE 64 5-ALPHA REDUCTASE INHIBITORS MARKET, BY REGION,
2022–2030 (USD MILLION) 114
TABLE 65 NORTH AMERICA: 5-ALPHA REDUCTASE INHIBITORS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 114
TABLE 66 EUROPE: 5-ALPHA REDUCTASE INHIBITORS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 115
TABLE 67 ASIA PACIFIC: 5-ALPHA REDUCTASE INHIBITORS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 115
TABLE 68 LATIN AMERICA: 5-ALPHA REDUCTASE INHIBITORS MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 116
TABLE 69 5-ALPHA REDUCTASE INHIBITORS FOR DUTASTERIDE MARKET, BY REGION,
2022–2030 (USD MILLION) 116
TABLE 70 NORTH AMERICA: 5-ALPHA REDUCTASE INHIBITORS MARKET FOR DUTASTERIDE, BY COUNTRY, 2022–2030 (USD MILLION) 117
TABLE 71 EUROPE: 5-ALPHA REDUCTASE INHIBITORS MARKET FOR DUTASTERIDE,
BY COUNTRY, 2022–2030 (USD MILLION) 117
TABLE 72 ASIA PACIFIC: 5-ALPHA REDUCTASE INHIBITORS MARKET FOR DUTASTERIDE,
BY COUNTRY, 2022–2030 (USD MILLION) 118
TABLE 73 LATIN AMERICA: 5-ALPHA REDUCTASE INHIBITORS MARKET FOR DUTASTERIDE,
BY COUNTRY, 2022–2030 (USD MILLION) 118
TABLE 74 5-ALPHA REDUCTASE INHIBITORS MARKET FOR FINASTERIDE, BY REGION,
2022–2030 (USD MILLION) 119
TABLE 75 NORTH AMERICA: 5-ALPHA REDUCTASE INHIBITORS MARKET FOR FINASTERIDE, BY COUNTRY, 2022–2030 (USD MILLION) 119
TABLE 76 EUROPE: 5-ALPHA REDUCTASE INHIBITORS MARKET FOR FINASTERIDE,
BY COUNTRY, 2022–2030 (USD MILLION) 120
TABLE 77 ASIA PACIFIC: 5-ALPHA REDUCTASE INHIBITORS MARKET FOR FINASTERIDE,
BY COUNTRY, 2022–2030 (USD MILLION) 120
TABLE 78 LATIN AMERICA: 5-ALPHA REDUCTASE INHIBITORS MARKET FOR FINASTERIDE,
BY COUNTRY, 2022–2030 (USD MILLION) 121
TABLE 79 OTHER DRUG TYPES MARKET, BY REGION, 2022–2030 (USD MILLION) 121
TABLE 80 NORTH AMERICA: OTHER DRUG TYPES MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 122
TABLE 81 EUROPE: OTHER DRUG TYPES MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 122
TABLE 82 ASIA PACIFIC: OTHER DRUG TYPES MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 122
TABLE 83 LATIN AMERICA: OTHER DRUG TYPES MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 123
TABLE 84 BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 125
TABLE 85 BPH TYPE MARKET, BY REGION, 2022–2030 (USD MILLION) 126
TABLE 86 NORTH AMERICA: BPH TYPE MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 126
TABLE 87 EUROPE: BPH TYPE MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 127
TABLE 88 ASIA PACIFIC: BPH TYPE MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 127
TABLE 89 LATIN AMERICA: BPH TYPE MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 128
TABLE 90 BPH SURGICAL TREATMENT MARKET FOR TURP, BY REGION,
2022–2030 (USD MILLION) 129
TABLE 91 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR TURP, BY COUNTRY, 2022–2030 (USD MILLION) 129
TABLE 92 EUROPE: BPH SURGICAL TREATMENT MARKET FOR TURP, BY COUNTRY,
2022–2030 (USD MILLION) 130
TABLE 93 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR TURP, BY COUNTRY, 2022–2030 (USD MILLION) 130
TABLE 94 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR TURP, BY COUNTRY, 2022–2030 (USD MILLION) 131
TABLE 95 BPH SURGICAL TREATMENT MARKET FOR LASER SURGERIES, BY REGION,
2022–2030 (USD MILLION) 131
TABLE 96 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR LASER SURGERIES, BY COUNTRY, 2022–2030 (USD MILLION) 132
TABLE 97 EUROPE: BPH SURGICAL TREATMENT MARKET FOR LASER SURGERIES,
BY COUNTRY, 2022–2030 (USD MILLION) 132
TABLE 98 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR LASER SURGERIES,
BY COUNTRY, 2022–2030 (USD MILLION) 133
TABLE 99 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR LASER SURGERIES,
BY COUNTRY, 2022–2030 (USD MILLION) 133
TABLE 100 BPH SURGICAL TREATMENT MARKET FOR UROLIFT PROCEDURES, BY REGION, 2022–2030 (USD MILLION) 134
TABLE 101 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR UROLIFT PROCEDURES, BY COUNTRY, 2022–2030 (USD MILLION) 134
TABLE 102 EUROPE: BPH SURGICAL TREATMENT MARKET FOR UROLIFT PROCEDURES,
BY COUNTRY, 2022–2030 (USD MILLION) 135
TABLE 103 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR UROLIFT PROCEDURES, BY COUNTRY, 2022–2030 (USD MILLION) 135
TABLE 104 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR UROLIFT PROCEDURES, BY COUNTRY, 2022–2030 (USD MILLION) 136
TABLE 105 BPH SURGICAL TREATMENT MARKET FOR REZŪM PROCEDURES, BY REGION, 2022–2030 (USD MILLION) 136
TABLE 106 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR REZŪM PROCEDURES, BY COUNTRY, 2022–2030 (USD MILLION) 137
TABLE 107 EUROPE: BPH SURGICAL TREATMENT MARKET FOR REZŪM PROCEDURES,
BY COUNTRY, 2022–2030 (USD MILLION) 137
TABLE 108 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR REZŪM PROCEDURES,
BY COUNTRY, 2022–2030 (USD MILLION) 138
TABLE 109 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR REZŪM PROCEDURES, BY COUNTRY, 2022–2030 (USD MILLION) 138
TABLE 110 BPH SURGICAL TREATMENT MARKET FOR ROBOT-ASSISTED WATERJET ABLATION, BY REGION, 2022–2030 (USD MILLION) 139
TABLE 111 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR ROBOT-ASSISTED WATERJET ABLATION, BY COUNTRY, 2022–2030 (USD MILLION) 139
TABLE 112 EUROPE: BPH SURGICAL TREATMENT MARKET FOR ROBOT-ASSISTED WATERJET ABLATION, BY COUNTRY, 2022–2030 (USD MILLION) 140
TABLE 113 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR ROBOT-ASSISTED WATERJET ABLATION, BY COUNTRY, 2022–2030 (USD MILLION) 140
TABLE 114 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR ROBOT-ASSISTED WATERJET ABLATION, BY COUNTRY, 2022–2030 (USD MILLION) 141
TABLE 115 BPH SURGICAL TREATMENT MARKET FOR PROSTATIC STENTING, BY REGION, 2022–2030 (USD MILLION) 142
TABLE 116 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR PROSTATIC STENTS, BY COUNTRY, 2022–2030 (USD MILLION) 142
TABLE 117 EUROPE: BPH SURGICAL TREATMENT MARKET FOR PROSTATIC STENTS,
BY COUNTRY, 2022–2030 (USD MILLION) 143
TABLE 118 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR PROSTATIC STENTS,
BY COUNTRY, 2022–2030 (USD MILLION) 143
TABLE 119 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR PROSTATIC STENTS,
BY COUNTRY, 2022–2030 (USD MILLION) 144
TABLE 120 BPH SURGICAL TREATMENT MARKET FOR TUMT, BY REGION,
2022–2030 (USD MILLION) 144
TABLE 121 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR TUMT, BY COUNTRY, 2022–2030 (USD MILLION) 145
TABLE 122 EUROPE: BPH SURGICAL TREATMENT MARKET FOR TUMT, BY COUNTRY,
2022–2030 (USD MILLION) 145
TABLE 123 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR TUMT, BY COUNTRY, 2022–2030 (USD MILLION) 146
TABLE 124 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR TUMT, BY COUNTRY, 2022–2030 (USD MILLION) 146
TABLE 125 BPH SURGICAL TREATMENT MARKET FOR TUNA, BY REGION,
2022–2030 (USD MILLION) 147
TABLE 126 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR TUNA, BY COUNTRY, 2022–2030 (USD MILLION) 147
TABLE 127 EUROPE: BPH SURGICAL TREATMENT MARKET FOR TUNA, BY COUNTRY,
2022–2030 (USD MILLION) 148
TABLE 128 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR TUNA, BY COUNTRY, 2022–2030 (USD MILLION) 148
TABLE 129 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR TUNA, BY COUNTRY, 2022–2030 (USD MILLION) 149
TABLE 130 BPH SURGICAL TREATMENT MARKET FOR PAE, BY REGION,
2022–2030 (USD MILLION) 150
TABLE 131 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR PAE, BY COUNTRY, 2022–2030 (USD MILLION) 150
TABLE 132 EUROPE: BPH SURGICAL TREATMENT MARKET FOR PAE, BY COUNTRY,
2022–2030 (USD MILLION) 151
TABLE 133 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR PAE, BY COUNTRY,
2022–2030 (USD MILLION) 151
TABLE 134 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR PAE, BY COUNTRY, 2022–2030 (USD MILLION) 152
TABLE 135 BPH SURGICAL TREATMENT MARKET FOR OTHER PROCEDURES, BY REGION, 2022–2030 (USD MILLION) 152
TABLE 136 NORTH AMERICA: BPH DRUG TREATMENT MARKET FOR OTHER PROCEDURES,
BY COUNTRY, 2022–2030 (USD MILLION) 153
TABLE 137 EUROPE: BPH DRUG TREATMENT MARKET FOR OTHER PROCEDURES,
BY COUNTRY, 2022–2030 (USD MILLION) 153
TABLE 138 ASIA PACIFIC: BPH DRUG TREATMENT MARKET FOR OTHER PROCEDURES,
BY COUNTRY, 2022–2030 (USD MILLION) 154
TABLE 139 LATIN AMERICA: BPH DRUG TREATMENT MARKET FOR OTHER PROCEDURES,
BY COUNTRY, 2022–2030 (USD MILLION) 154
TABLE 140 BPH THERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION) 156
TABLE 141 BPH THERAPY MARKET, BY REGION, 2022–2030 (USD MILLION) 156
TABLE 142 NORTH AMERICA: BPH THERAPY MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 157
TABLE 143 EUROPE: BPH THERAPY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 157
TABLE 144 ASIA PACIFIC: BPH THERAPY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 157
TABLE 145 LATIN AMERICA: BPH THERAPY MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 158
TABLE 146 MONOTHERAPY MARKET, BY REGION, 2022–2030 (USD MILLION) 158
TABLE 147 NORTH AMERICA: MONOTHERAPY MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 159
TABLE 148 EUROPE: MONOTHERAPY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 159
TABLE 149 ASIA PACIFIC: MONOTHERAPY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 159
TABLE 150 LATIN AMERICA: MONOTHERAPY MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 160
TABLE 151 COMBINATION DRUG THERAPY MARKET, BY REGION, 2022–2030 (USD MILLION) 161
TABLE 152 NORTH AMERICA: COMBINATION DRUG THERAPY MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 161
TABLE 153 EUROPE: COMBINATION DRUG THERAPY MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 162
TABLE 154 ASIA PACIFIC: COMBINATION DRUG THERAPY MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 162
TABLE 155 LATIN AMERICA: COMBINATION DRUG THERAPY MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 163
TABLE 156 BPH SURGICAL TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION) 165
TABLE 157 BPH SURGICAL TREATMENT MARKET FOR HOSPITALS, BY REGION,
2022–2030 (USD MILLION) 166
TABLE 158 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR HOSPITALS,
BY COUNTRY, 2022–2030 (USD MILLION) 166
TABLE 159 EUROPE: BPH SURGICAL TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2022–2030 (USD MILLION) 167
TABLE 160 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR HOSPITALS,
BY COUNTRY, 2022–2030 (USD MILLION) 167
TABLE 161 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR HOSPITALS,
BY COUNTRY, 2022–2030 (USD MILLION) 168
TABLE 162 BPH SURGICAL TREATMENT MARKET FOR ASCS & CLINICS, BY REGION,
2022–2030 (USD MILLION) 169
TABLE 163 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR ASCS & CLINICS,
BY COUNTRY, 2022–2030 (USD MILLION) 169
TABLE 164 EUROPE: BPH SURGICAL TREATMENT MARKET FOR ASCS & CLINICS, BY COUNTRY, 2022–2030 (USD MILLION) 170
TABLE 165 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR ASCS & CLINICS,
BY COUNTRY, 2022–2030 (USD MILLION) 170
TABLE 166 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR ASCS & CLINICS,
BY COUNTRY, 2022–2030 (USD MILLION) 171
TABLE 167 BPH SURGICAL TREATMENT MARKET FOR HOME CARE SETTINGS, BY REGION, 2022–2030 (USD MILLION) 172
TABLE 168 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION) 172
TABLE 169 EUROPE: BPH SURGICAL TREATMENT MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022–2030 (USD MILLION) 173
TABLE 170 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022–2030 (USD MILLION) 173
TABLE 171 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION) 174
TABLE 172 BPH SURGICAL TREATMENT MARKET, BY REGION, 2022–2030 (USD MILLION) 176
TABLE 173 GLOBAL: ROBOT-ASSISTED WATERJET ABLATION SYSTEMS SOLD,
2022–2030 (MILLION UNITS) 176
TABLE 174 NORTH AMERICA: MACROINDICATORS 177
TABLE 175 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 178
TABLE 176 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE,
2022–2030 (USD MILLION) 179
TABLE 177 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS,
BY TYPE, 2022–2030 (USD MILLION) 179
TABLE 178 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 179
TABLE 179 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET, BY TYPE,
2022–2030 (USD MILLION) 180
TABLE 180 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET, BY THERAPY,
2022–2030 (USD MILLION) 180
TABLE 181 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET, BY END USER,
2022–2030 (USD MILLION) 181
TABLE 182 US: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE,
2022–2030 (USD MILLION) 182
TABLE 183 US: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE,
2022–2030 (USD MILLION) 182
TABLE 184 US: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 182
TABLE 185 US: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 183
TABLE 186 US: BPH SURGICAL TREATMENT MARKET, BY THERAPY,
2022–2030 (USD MILLION) 183
TABLE 187 US: BPH SURGICAL TREATMENT MARKET, BY END USER,
2022–2030 (USD MILLION) 184
TABLE 188 CANADA: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE,
2022–2030 (USD MILLION) 185
TABLE 189 CANADA: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 185
TABLE 190 CANADA: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 185
TABLE 191 CANADA: BPH SURGICAL TREATMENT MARKET, BY TYPE,
2022–2030 (USD MILLION) 186
TABLE 192 CANADA: BPH SURGICAL TREATMENT MARKET, BY THERAPY,
2022–2030 (USD MILLION) 186
TABLE 193 CANADA: BPH SURGICAL TREATMENT MARKET, BY END USER,
2022–2030 (USD MILLION) 187
TABLE 194 EUROPE: MACROINDICATORS 188
TABLE 195 EUROPE: BPH SURGICAL TREATMENT MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 188
TABLE 196 EUROPE: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE,
2022–2030 (USD MILLION) 189
TABLE 197 EUROPE: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 189
TABLE 198 EUROPE: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 189
TABLE 199 EUROPE: BPH SURGICAL TREATMENT MARKET, BY TYPE,
2022–2030 (USD MILLION) 190
TABLE 200 EUROPE: BPH SURGICAL TREATMENT MARKET, BY THERAPY,
2022–2030 (USD MILLION) 190
TABLE 201 EUROPE: BPH SURGICAL TREATMENT MARKET, BY END USER,
2022–2030 (USD MILLION) 191
TABLE 202 GERMANY: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE,
2022–2030 (USD MILLION) 192
TABLE 203 GERMANY: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 192
TABLE 204 GERMANY: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 192
TABLE 205 GERMANY: BPH SURGICAL TREATMENT MARKET, BY TYPE,
2022–2030 (USD MILLION) 193
TABLE 206 GERMANY: BPH SURGICAL TREATMENT MARKET, BY THERAPY,
2022–2030 (USD MILLION) 193
TABLE 207 GERMANY: BPH SURGICAL TREATMENT MARKET, BY END USER,
2022–2030 (USD MILLION) 194
TABLE 208 UK: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE,
2022–2030 (USD MILLION) 195
TABLE 209 UK: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE,
2022–2030 (USD MILLION) 195
TABLE 210 UK: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 195
TABLE 211 UK: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 196
TABLE 212 UK: BPH SURGICAL TREATMENT MARKET, BY THERAPY,
2022–2030 (USD MILLION) 196
TABLE 213 UK: BPH SURGICAL TREATMENT MARKET, BY END USER,
2022–2030 (USD MILLION) 197
TABLE 214 FRANCE: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE,
2022–2030 (USD MILLION) 198
TABLE 215 FRANCE: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS,
BY TYPE, 2022–2030 (USD MILLION) 198
TABLE 216 FRANCE: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 198
TABLE 217 FRANCE: BPH SURGICAL TREATMENT MARKET, BY TYPE,
2022–2030 (USD MILLION) 199
TABLE 218 FRANCE: BPH SURGICAL TREATMENT MARKET, BY THERAPY,
2022–2030 (USD MILLION) 199
TABLE 219 FRANCE: BPH SURGICAL TREATMENT MARKET, BY END USER,
2022–2030 (USD MILLION) 200
TABLE 220 ITALY: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE,
2022–2030 (USD MILLION) 200
TABLE 221 ITALY: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 201
TABLE 222 ITALY: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 201
TABLE 223 ITALY: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 202
TABLE 224 ITALY: BPH SURGICAL TREATMENT MARKET, BY THERAPY,
2022–2030 (USD MILLION) 202
TABLE 225 ITALY: BPH SURGICAL TREATMENT MARKET, BY END USER,
2022–2030 (USD MILLION) 203
TABLE 226 SPAIN: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE,
2022–2030 (USD MILLION) 203
TABLE 227 SPAIN: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 204
TABLE 228 SPAIN: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 204
TABLE 229 SPAIN: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 205
TABLE 230 SPAIN: BPH SURGICAL TREATMENT MARKET, BY THERAPY,
2022–2030 (USD MILLION) 205
TABLE 231 SPAIN: BPH SURGICAL TREATMENT MARKET, BY END USER,
2022–2030 (USD MILLION) 206
TABLE 232 REST OF EUROPE: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE,
2022–2030 (USD MILLION) 206
TABLE 233 REST OF EUROPE: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS,
BY TYPE, 2022–2030 (USD MILLION) 207
TABLE 234 REST OF EUROPE: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 207
TABLE 235 REST OF EUROPE: BPH SURGICAL TREATMENT MARKET, BY TYPE,
2022–2030 (USD MILLION) 208
TABLE 236 REST OF EUROPE: BPH SURGICAL TREATMENT MARKET, BY THERAPY,
2022–2030 (USD MILLION) 208
TABLE 237 REST OF EUROPE: BPH SURGICAL TREATMENT MARKET, BY END USER,
2022–2030 (USD MILLION) 209
TABLE 238 ASIA PACIFIC: MACROINDICATORS 209
TABLE 239 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 211
TABLE 240 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE,
2022–2030 (USD MILLION) 211
TABLE 241 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS,
BY TYPE, 2022–2030 (USD MILLION) 212
TABLE 242 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 212
TABLE 243 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY TYPE,
2022–2030 (USD MILLION) 213
TABLE 244 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY THERAPY,
2022–2030 (USD MILLION) 213
TABLE 245 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY END USER,
2022–2030 (USD MILLION) 214
TABLE 246 JAPAN: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE,
2022–2030 (USD MILLION) 215
TABLE 247 JAPAN: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 215
TABLE 248 JAPAN: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 215
TABLE 249 JAPAN: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 216
TABLE 250 JAPAN: BPH SURGICAL TREATMENT MARKET, BY THERAPY,
2022–2030 (USD MILLION) 216
TABLE 251 JAPAN: BPH SURGICAL TREATMENT MARKET, BY END USER,
2022–2030 (USD MILLION) 217
TABLE 252 CHINA: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE,
2022–2030 (USD MILLION) 218
TABLE 253 CHINA: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 218
TABLE 254 CHINA: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 219
TABLE 255 CHINA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 219
TABLE 256 CHINA: BPH SURGICAL TREATMENT MARKET, BY THERAPY,
2022–2030 (USD MILLION) 220
TABLE 257 CHINA: BPH SURGICAL TREATMENT MARKET, BY END USER,
2022–2030 (USD MILLION) 220
TABLE 258 INDIA: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE,
2022–2030 (USD MILLION) 221
TABLE 259 INDIA: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 221
TABLE 260 INDIA: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 221
TABLE 261 INDIA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 222
TABLE 262 INDIA: BPH SURGICAL TREATMENT MARKET, BY THERAPY,
2022–2030 (USD MILLION) 222
TABLE 263 INDIA: BPH SURGICAL TREATMENT MARKET, BY END USER,
2022–2030 (USD MILLION) 223
TABLE 264 AUSTRALIA: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE,
2022–2030 (USD MILLION) 223
TABLE 265 AUSTRALIA: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 224
TABLE 266 AUSTRALIA: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 224
TABLE 267 AUSTRALIA: BPH SURGICAL TREATMENT MARKET, BY TYPE,
2022–2030 (USD MILLION) 225
TABLE 268 AUSTRALIA: BPH SURGICAL TREATMENT MARKET, BY THERAPY,
2022–2030 (USD MILLION) 225
TABLE 269 AUSTRALIA: BPH SURGICAL TREATMENT MARKET, BY END USER,
2022–2030 (USD MILLION) 226
TABLE 270 REST OF ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022–2030 (USD MILLION) 227
TABLE 271 REST OF ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 227
TABLE 272 REST OF ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 227
TABLE 273 REST OF ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY TYPE,
2022–2030 (USD MILLION) 228
TABLE 274 REST OF ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY THERAPY,
2022–2030 (USD MILLION) 228
TABLE 275 REST OF ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION) 229
TABLE 276 LATIN AMERICA: MACROINDICATORS 229
TABLE 277 LATIN AMERICA BPH SURGICAL TREATMENT MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 230
TABLE 278 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE,
2022–2030 (USD MILLION) 230
TABLE 279 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS,
BY TYPE, 2022–2030 (USD MILLION) 230
TABLE 280 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 231
TABLE 281 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET, BY TYPE,
2022–2030 (USD MILLION) 231
TABLE 282 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET, BY THERAPY,
2022–2030 (USD MILLION) 232
TABLE 283 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET, BY END USER,
2022–2030 (USD MILLION) 232
TABLE 284 BRAZIL: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE,
2022–2030 (USD MILLION) 233
TABLE 285 BRAZIL: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS,
BY TYPE, 2022–2030 (USD MILLION) 233
TABLE 286 BRAZIL: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 233
TABLE 287 BRAZIL: BPH SURGICAL TREATMENT MARKET, BY TYPE,
2022–2030 (USD MILLION) 234
TABLE 288 BRAZIL: BPH SURGICAL TREATMENT MARKET, BY THERAPY,
2022–2030 (USD MILLION) 234
TABLE 289 BRAZIL: BPH SURGICAL TREATMENT MARKET, BY END USER,
2022–2030 (USD MILLION) 235
TABLE 290 MEXICO: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE,
2022–2030 (USD MILLION) 236
TABLE 291 MEXICO: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS,
BY TYPE, 2022–2030 (USD MILLION) 236
TABLE 292 MEXICO: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 236
TABLE 293 MEXICO: BPH SURGICAL TREATMENT MARKET, BY TYPE,
2022–2030 (USD MILLION) 237
TABLE 294 MEXICO: BPH SURGICAL TREATMENT MARKET, BY THERAPY,
2022–2030 (USD MILLION) 237
TABLE 295 MEXICO: BPH SURGICAL TREATMENT MARKET, BY END USER,
2022–2030 (USD MILLION) 238
TABLE 296 REST OF LATIN AMERICA: BPH SURGICAL TREATMENT MARKET,
BY DRUG TYPE, 2022–2030 (USD MILLION) 238
TABLE 297 REST OF LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 239
TABLE 298 REST OF LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 239
TABLE 299 REST OF LATIN AMERICA: BPH SURGICAL TREATMENT MARKET, BY TYPE,
2022–2030 (USD MILLION) 240
TABLE 300 REST OF LATIN AMERICA: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022–2030 (USD MILLION) 240
TABLE 301 REST OF LATIN AMERICA: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION) 241
TABLE 302 MIDDLE EAST & AFRICA: MACROINDICATORS 242
TABLE 303 MIDDLE EAST & AFRICA: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022–2030 (USD MILLION) 243
TABLE 304 MIDDLE EAST & AFRICA: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 243
TABLE 305 MIDDLE EAST & AFRICA: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 243
TABLE 306 MIDDLE EAST & AFRICA: BPH SURGICAL TREATMENT MARKET, BY TYPE,
2022–2030 (USD MILLION) 244
TABLE 307 MIDDLE EAST & AFRICA: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022–2030 (USD MILLION) 244
TABLE 308 MIDDLE EAST & AFRICA: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION) 245
TABLE 309 GCC COUNTRIES: MACROINDICATORS 246
TABLE 310 GCC COUNTRIES: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE,
2022–2030 (USD MILLION) 246
TABLE 311 GCC COUNTRIES: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS,
BY TYPE, 2022–2030 (USD MILLION) 247
TABLE 312 GCC COUNTRIES: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 247
TABLE 313 GCC COUNTRIES: BPH SURGICAL TREATMENT MARKET, BY TYPE,
2022–2030 (USD MILLION) 248
TABLE 314 GCC COUNTRIES: BPH SURGICAL TREATMENT MARKET, BY THERAPY,
2022–2030 (USD MILLION) 248
TABLE 315 GCC COUNTRIES: BPH SURGICAL TREATMENT MARKET, BY END USER,
2022–2030 (USD MILLION) 249
TABLE 316 OVERVIEW OF STRATEGIES ADOPTED BY KEY MARKET PLAYERS 250
TABLE 317 BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE: DEGREE OF COMPETITION 253
TABLE 318 BPH SURGICAL TREATMENT MARKET, BY TYPE: DEGREE OF COMPETITION 255
TABLE 319 BPH SURGICAL TREATMENT MARKET: COMPANY FOOTPRINT 260
TABLE 320 BPH SURGICAL TREATMENT MARKET: REGION FOOTPRINT 261
TABLE 321 BPH SURGICAL TREATMENT MARKET: DRUG TYPE FOOTPRINT 261
TABLE 322 BPH SURGICAL TREATMENT MARKET: TYPE FOOTPRINT 262
TABLE 323 BPH SURGICAL TREATMENT MARKET: END-USER FOOTPRINT 262
TABLE 324 BPH SURGICAL TREATMENT MARKET: DETAILED LIST OF KEY SME PLAYERS 265
TABLE 325 BPH SURGICAL TREATMENT MARKET: COMPETITIVE BENCHMARKING
OF KEY STARTUPS 265
TABLE 326 BPH SURGICAL TREATMENT MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–JANUARY 2025 267
TABLE 327 BPH SURGICAL TREATMENT MARKET: DEALS, JANUARY 2021–JANUARY 2025 268
TABLE 328 BPH SURGICAL TREATMENT MARKET: EXPANSIONS,
JANUARY 2021–JANUARY 2025 269
TABLE 329 GLAXOSMITHKLINE PLC: COMPANY OVERVIEW 270
TABLE 330 GLAXOSMITHKLINE PLC: PRODUCTS OFFERED 272
TABLE 331 GLAXOSMITHKLINE PLC: DEALS, JANUARY 2021–JANUARY 2025 272
TABLE 332 ELI LILLY AND COMPANY: COMPANY OVERVIEW 274
TABLE 333 ELI LILLY AND COMPANY: PRODUCTS OFFERED 275
TABLE 334 ELI LILLY AND COMPANY: DEALS, JANUARY 2021–JANUARY 2025 276
TABLE 335 TELEFLEX INCORPORATED: COMPANY OVERVIEW 277
TABLE 336 TELEFLEX INCORPORATED: PRODUCTS OFFERED 278
TABLE 337 TELEFLEX INCORPORATED: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2021–JANUARY 2025 279
TABLE 338 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW 281
TABLE 339 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED 282
TABLE 340 BOSTON SCIENTIFIC CORPORATION: DEALS, JANUARY 2021–JANUARY 2025 283
TABLE 341 BOSTON SCIENTIFIC CORPORATION: EXPANSIONS, JANUARY 2021–JANUARY 2025 283
TABLE 342 PROCEPT BIOROBOTICS CORPORATION: COMPANY OVERVIEW 285
TABLE 343 PROCEPT BIOROBOTICS CORPORATION: PRODUCTS OFFERED 286
TABLE 344 PROCEPT BIOROBOTICS CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–JANUARY 2025 287
TABLE 345 PROCEPT BIOROBOTICS CORPORATION: EXPANSIONS,
JANUARY 2021–JANUARY 2025 287
TABLE 346 ASTELLAS PHARMA INC.: COMPANY OVERVIEW 289
TABLE 347 ASTELLAS PHARMA INC.: PRODUCTS OFFERED 290
TABLE 348 ALEMBIC PHARMACEUTICALS LIMITED: COMPANY OVERVIEW 291
TABLE 349 ALEMBIC PHARMACEUTICALS LIMITED: PRODUCTS OFFERED 292
TABLE 350 ASAHI KASEI CORPORATION: COMPANY OVERVIEW 293
TABLE 351 ASAHI KASEI CORPORATION: PRODUCTS OFFERED 295
TABLE 352 ORGANON & CO.: COMPANY OVERVIEW 296
TABLE 353 ORGANON & CO.: PRODUCTS OFFERED 297
TABLE 354 ORGANON & CO.: DEALS, JANUARY 2021–JANUARY 2025 297
TABLE 355 OLYMPUS CORPORATION: COMPANY OVERVIEW 298
TABLE 356 OLYMPUS CORPORATION: PRODUCTS OFFERED 300
TABLE 357 OLYMPUS CORPORATION: DEALS, JANUARY 2021–JANUARY 2021 300
TABLE 358 COLOPLAST GROUP: COMPANY OVERVIEW 301
TABLE 359 COLOPLAST GROUP: PRODUCTS OFFERED 303
TABLE 360 IPG PHOTONICS CORPORATION: COMPANY OVERVIEW 304
TABLE 361 IPG PHOTONICS CORPORATION: PRODUCTS OFFERED 305
TABLE 362 VIATRIS INC.: COMPANY OVERVIEW 306
TABLE 363 VIATRIS INC.: PRODUCTS OFFERED 307
TABLE 364 ABBVIE INC.: COMPANY OVERVIEW 308
TABLE 365 ABBVIE INC.: PRODUCTS OFFERED 309
TABLE 366 ABBVIE INC.: DEALS, JANUARY 2021–JANUARY 2025 310
TABLE 367 PROSTALUND AB: COMPANY OVERVIEW 311
TABLE 368 PROSTALUND AB: PRODUCTS OFFERED 312
LIST OF FIGURES
FIGURE 1 MARKETS & REGIONS COVERED 30
FIGURE 2 RESEARCH DESIGN 34
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 38
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 39
FIGURE 5 BPH SURGICAL TREATMENT MARKET: REVENUE ESTIMATION APPROACH, BY TYPE 40
FIGURE 6 BPH SURGICAL TREATMENT MARKET: REVENUE ESTIMATION APPROACH,
BY DRUG TYPE 41
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 43
FIGURE 8 BPH SURGICAL TREATMENT MARKET: TOP-DOWN APPROACH 44
FIGURE 9 DATA TRIANGULATION METHODOLOGY 45
FIGURE 10 BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE,
2024 VS. 2030 (USD MILLION) 48
FIGURE 11 BPH SURGICAL TREATMENT MARKET, BY TYPE, 2024 VS. 2030 (USD MILLION) 49
FIGURE 12 BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2024 VS. 2030 (USD MILLION) 50
FIGURE 13 BPH SURGICAL TREATMENT, BY END USER, 2024 VS. 2030 (USD MILLION) 51
FIGURE 14 GEOGRAPHIC SNAPSHOT OF BPH SURGICAL TREATMENT MARKET 52
FIGURE 15 EXPANDING GERIATRIC POPULATION AND INCREASING PREVALENCE OF BENIGN PROSTATIC HYPERPLASIA TO PROPEL MARKET 53
FIGURE 16 ALPHA-BLOCKERS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE
IN US IN 2023 54
FIGURE 17 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 55
FIGURE 18 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 56
FIGURE 19 BPH TREATMENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 57
FIGURE 20 BHP SURGICAL TREATMENT MARKET: MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASES 65
FIGURE 21 BPH SURGICAL TREATMENT MARKET: SUPPLY CHAIN ANALYSIS 66
FIGURE 22 BPH SURGICAL TREATMENT MARKET: ECOSYSTEM ANALYSIS 67
FIGURE 23 KEY PLAYERS IN BPH SURGICAL TREATMENT MARKET ECOSYSTEM 68
FIGURE 24 BPH SURGICAL TREATMENT MARKET: PORTER’S FIVE FORCES ANALYSIS 69
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR BPH SURGICAL TREATMENT MARKET 71
FIGURE 26 KEY BUYING CRITERIA FOR BPH SURGICAL TREATMENT, BY END USER 71
FIGURE 27 BPH SURGICAL TREATMENT MARKET: PESTLE ANALYSIS 85
FIGURE 28 PATENT ANALYSIS FOR PROSTATIC STENTS: JANUARY 2015–DECEMBER 2024 86
FIGURE 29 PATENT ANALYSIS FOR TRANSURETHRAL CATHETERS:
JANUARY 2015–DECEMBER 2024 87
FIGURE 30 PATENT ANALYSIS FOR AVODART: JANUARY 2015–DECEMBER 2024 88
FIGURE 31 PATENT ANALYSIS FOR ALFUZOSIN: JANUARY 2015–DECEMBER 2024 89
FIGURE 32 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESSES IN BPH SURGICAL TREATMENT MARKET 93
FIGURE 33 BPH SURGICAL TREATMENT MARKET: NUMBER OF DEALS & VENTURES 94
FIGURE 34 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET SNAPSHOT 178
FIGURE 35 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET SNAPSHOT 210
FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS IN BPH SURGICAL TREATMENT, 2021−2023 252
FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS IN BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE (2023) 253
FIGURE 38 MARKET SHARE ANALYSIS OF KEY PLAYERS IN BPH SURGICAL TREATMENT MARKET, BY TYPE (2023) 254
FIGURE 39 BPH SURGICAL TREATMENT MARKET: COMPANY EVALUATION MATRIX FOR DRUG TYPE (KEY PLAYERS), 2023 257
FIGURE 40 BPH SURGICAL TREATMENT MARKET: COMPANY EVALUATION MATRIX FOR TYPE, (KEY PLAYERS), 2023 259
FIGURE 41 BPH SURGICAL TREATMENT MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 264
FIGURE 42 EV/EBITDA OF KEY VENDORS, 2023−2024 266
FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA
OF KEY VENDORS 266
FIGURE 44 BPH SURGICAL TREATMENT MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 267
FIGURE 45 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2023) 271
FIGURE 46 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2023) 275
FIGURE 47 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2023) 278
FIGURE 48 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2023) 282
FIGURE 49 PROCEPT BIOROBOTICS CORPORATION: COMPANY SNAPSHOT (2023) 286
FIGURE 50 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2023) 289
FIGURE 51 ALEMBIC PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT (2023) 291
FIGURE 52 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2023) 294
FIGURE 53 ORGANON & CO.: COMPANY SNAPSHOT (2023) 296
FIGURE 54 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2023) 299
FIGURE 55 COLOPLAST GROUP: COMPANY SNAPSHOT (2024) 302
FIGURE 56 IPG PHOTONICS CORPORATION: COMPANY SNAPSHOT (2023) 305
FIGURE 57 VIATRIS INC.: COMPANY SNAPSHOT (2023) 306
FIGURE 58 ABBVIE INC.: COMPANY SNAPSHOT (2023) 309
FIGURE 59 PROSTALUND AB: COMPANY SNAPSHOT (2023) 311
MarketsandMarkets（マーケッツアンドマーケッツ）は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- ご注文後2営業日以内
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
割引可能なレポートが多数ございます。価格・サンプルについてはお気軽にご相談ください。
最新調査レポート
- 尿失禁デバイス市場 – 2030年までの世界予測 2025-03-12
- 医療用加湿器市場 – 2029年までの世界予測 2025-03-11
- BOPETフィルム市場 – 2029年までの世界予測 2025-03-11
- 金ナノ粒子市場 – 2029年までの世界予測 2025-03-07
- 沈降シリカ市場 – 2030年までの世界予測 2025-03-07